XPO1 mutations were identified in 176/4580 (3.8%) cases with most mutations detected in U-CLL (88%), patients requiring treatment (90%) and patients carrying mutations in a second gene (97/176, 55.1%). Here, XPO1 is linked to B-cell chronic lymphocytic leukemia.